Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the decision to submit a Biologics License Application (BLA) in the U.S. for ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and ...

monoclonal antibodies, such as cetuximab and panitumumab, directed against the extracellular domain of EGFR, and tyrosine kinase inhibitors, like gefitinib and erlotinib, which block the kinase ...

The initial project will focus on antibodies’ design with agonistic function for a demanding GPCR target. Credit: SmartPhotoLab/Shutterstock. Nxera Pharma ...

The delay “does not impact our MRUS thesis,” he added. Petosemtamab is a human, full-length IgG1 monoclonal antibody designed to bind to EGFR and LGR5, both of which are known cancer targets.

of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases ...